- Cytodyn Inc Company Update Call TranscriptDec 14, 2023
- Cytodyn Inc Annual Shareholders Meeting TranscriptNov 09, 2023
- Cytodyn Inc Investment Community Webcast TranscriptJul 24, 2023
- Cytodyn Inc To Provide a Company Update TranscriptApr 11, 2023
- Cytodyn Inc Investment Community Webcast TranscriptDec 29, 2022
- Cytodyn Inc To Host R&D Update-Virtual TranscriptDec 07, 2022
- Cytodyn Inc Investment Community Webcast TranscriptOct 31, 2022
- Cytodyn Inc Investment Community Webcast TranscriptSep 28, 2022
- Cytodyn Inc Investment Community Webcast TranscriptMar 31, 2022
- Cytodyn Inc Investment Community Webcast TranscriptMar 08, 2021
- Cytodyn Inc with Dr.Pourhassan gives an update on CytoDyn's COVID-19 path and more on Proactive TranscriptOct 24, 2020
- Cytodyn Inc Investor Call TranscriptSep 02, 2020
- Cytodyn Inc To Host Investment Community Conference Call TranscriptAug 12, 2020
- Cytodyn Inc Dr. Nader Pourhassan, CytoDyn's CEO, Addresses The False Claims Made By STAT News TranscriptJul 31, 2020
- Cytodyn Inc Special Meeting TranscriptJul 29, 2020
- Cytodyn Inc InvestTalk TranscriptJul 24, 2020
- Cytodyn Inc Dr. Pourhassan Discusses Citron Research's False Report TranscriptJul 02, 2020
- Cytodyn Inc Developing New Therapies for Treatment of Human Immunodeficiency Virus TranscriptJun 18, 2020
- Cytodyn Inc To Host Investment Community Conference Call TranscriptJun 13, 2020
- Cytodyn Inc To Host Investor Community Conference Call TranscriptJun 11, 2020
- Cytodyn Inc Discussion on Company's Trials and COVID19 on Crush the Street Call TranscriptJun 07, 2020
- Cytodyn Inc at CytoDyn (OTC: CYDY) June 2 2020 - Livestream TranscriptJun 02, 2020
- Cytodyn Inc Investor Community Conference Call TranscriptMay 26, 2020
- Cytodyn Inc CytoDyn on Wall Street Reporter with Drs. Pourhassan, Lalezari, and Patterson TranscriptMay 21, 2020
- Cytodyn Inc at Lee Kelso discusses Leronlimab on WOWO radio TranscriptMay 20, 2020
- Cytodyn Inc Shares Manuscript Of Potential Coronavirus Treatment TranscriptMay 07, 2020
- Cytodyn Inc Leronlimab For COVID-19 Coronavirus Treatment TranscriptMay 02, 2020
- Cytodyn Inc Wall Street Reporter TranscriptMay 01, 2020
- Cytodyn Inc At This Drug is Now a Leading Contender to Treat COVID-19 TranscriptApr 27, 2020
- Cytodyn Inc COVID-19 Coronavirus Treatment Clinical Data Update TranscriptApr 18, 2020
- Cytodyn Inc Plans on Moving Forward With COVID-19 Trial TranscriptApr 13, 2020
- Cytodyn Inc at CytoDyn (OTC: CYDY) Coronaovirus Treatment gets FDA EMERGENCY IND + update on HIV & Cancer pipeline TranscriptMar 02, 2020
- Cytodyn Inc at This Week on RedChip TV: 3 Stocks Positioned for Upside in 2020 TranscriptFeb 19, 2020
- Cytodyn Inc at Cytodyn Inc Next Super Stock Live Hosted by Wall Street Reporter TranscriptFeb 11, 2020
- Cytodyn Inc Discusses New HIV Drug and Plans for Commercialization, Addressing $2 Billion Market Call TranscriptFeb 10, 2020
- Cytodyn Inc at Cytodyn Inc Next Super Stock Live Hosted by Wall Street Reporter TranscriptJan 23, 2020
Cytodyn Inc To Host Investment Community Conference Call Transcript
I will now turn the call over to Dr. Nader Pourhassan.
Thank you, Mike, and thank you, everyone, for being on this call. As of about an hour ago, CytoDyn has requested from the FDA to grant CytoDyn an Emergency Use Authorization for leronlimab based on CD10 data for mild-to-moderate COVID-19 population.
With that said, I would like to first discuss the results of our Phase 2 clinical trial, CD10. What is good outcome of a given Phase 2 and what is bad outcome? A best-case scenario for any Phase 2 is to be able to achieve a primary endpoint with a statistically significance value or any secondary endpoints with a statistically significant value.
Now, these items, these endpoints are listed on a Phase 2 because this is a proof of concept, so a sponsor of a drug development can find out which item wants to be the primary endpoint for the Phase 3 that will follow a successful Phase 2. Obviously, safety is very, very important. So a bad outcome would be if there is any problem with the safety that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)